Skip to content

Trial Objectives


Researchers want to know if a new medication, Saracatinib, is a more safe and effective treatment for Idiopathic Pulmonary Fibrosis (IPF) when compared to treatments that are currently available. 

Who Can Participate


Adults 40 years of age and older.

Age: 40+ Gender Any

Estimated Time Commitment


Not Specified

Time Commitment Details


Visits will take two to four hours.

Payment & Reimbursement


Payment Not Provided

Travel Reimbursement Not Available

Trial Contact


For more information, contact:

Kaitlin Fier
303.270.2852

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


National Institutes of Health

Principal Investigators

Gregory P. Downey

Gregory P. Downey, MD

Co-Investigators

Kevin K. Brown

Kevin K. Brown, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required